Background The optimal antithrombotic therapy following left atrial appendage occlusion
(LAAO) in patients with nonvalvular atrial fibrillation (AF) remains uncertain. Objectives In …

Non-valvular AF is a common clinical condition associated with an increased risk of
thromboembolic complications. As a consequence, oral anticoagulant therapy (OAT) is the …

Background In patients with end stage renal disease and atrial fibrillation (AF), undergoing
chronic dialysis, direct oral agents are contraindicated and warfarin does not fully prevent …

The optimal antiplatelet strategy after left atrial appendage (LAA) occlusion able to protect
from device-related thrombosis, paying the lowest price in terms of bleeding increase, is …

Background Intracranial hemorrhage (ICH) represents the most serious complication of oral
anticoagulant therapy (OAT) in patients with atrial fibrillation (AF), and AF patients with …

Background Transcatheter left atrial appendage occlusion (LAAO) has emerged as an
effective procedure for the prevention of thromboembolic events in non-valvular atrial …

Device-related thrombus (DRT) is a known complication occurring in up to 7% of patients
undergoing percutaneous left atrial appendage closure (LAAC). Since the target population …

Non-valvular atrial fibrillation (AF) and cerebral amyloid angiopathy (CAA) are two common
diseases in elderly populations. Despite the effectiveness of oral anticoagulant therapy in …

Our study aims to compare the utility of single antiplatelet therapy (SAPT) with dual
antiplatelet therapy (DAPT) following Left atrial appendage occlusion in patients whose post …

Objective Percutaneous left atrial appendage occlusion (LAAO) is an alternative strategy for
prevention of thromboembolic events in patients with atrial fibrillation and unsuitable for long …